Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 8/20 | 0.54 |
| ▸ | ITPR1 | Q14643 | 4/20 | 0.54 |
| ▸ | ITPR2 | Q14571 | 3/20 | 0.54 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.52 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.50 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7117013 | 1.00 | ITPR3 (0.54) | ITPR3ITPR1ITPR2INPP5ASMPD1 | |
| SCHEMBL1322462 | 1.00 | ITPR3 (0.54) | ITPR3ITPR1ITPR2INPP5ASMPD1 | |
| SCHEMBL133218 | 1.00 | ITPR3 (0.54) | ITPR3ITPR1ITPR2INPP5ASMPD1 | |
| SCHEMBL9742724 | 1.00 | ITPR3 (0.54) | ITPR3ITPR1ITPR2INPP5ASMPD1 | |
| SCHEMBL9165530 | 1.00 | ITPR3 (0.54) | ITPR3ITPR1ITPR2INPP5ASMPD1 | |
| SCHEMBL639515 | 1.00 | ITPR3 (0.54) | ITPR3ITPR1ITPR2INPP5ASMPD1 | |
| SCHEMBL462454 | 1.00 | ITPR3 (0.54) | ITPR3ITPR1ITPR2INPP5ASMPD1 | |
| SCHEMBL27550353 | 1.00 | ITPR3 (0.54) | ITPR3ITPR1ITPR2INPP5ASMPD1 | |
| SCHEMBL7171543 | 0.96 | ITPR3 (0.60) | ITPR3ITPR1ITPR2INPP5ASMPD1 | |
| SCHEMBL11233751 | 0.96 | ITPR3 (0.60) | ITPR3ITPR1ITPR2INPP5ASMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0730460-B1 | THE USE OF AN ESTER OF INOSITOLTRISPHOSPHATE FOR THE TREATMENT OF INFLAMMATORY CONDITIONS | PERSTORP AB (SE) | 2002-06-12 | — | — | EP | claimed |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
| WO-2025100535-A1 | COOLING STRUCTURE AND BATTERY UNIT | 日本製鉄株式会社 | 2025-05-15 | — | — | WO | disclosed |
| US-20240243386-A1 | COOLING STRUCTURE, BATTERY UNIT, AND MANUFACTURING METHOD OF COOLING STRUCTURE | NIPPON STEEL CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240154208-A1 | BATTERY UNIT | NIPPON STEEL CORPORATION (JP) | 2024-05-09 | — | — | US | disclosed |
| US-20240115595-A1 | MATERIAL COMPOSITIONS AND METHODS OF USE IMPROVING RNA STABILITY | TEAM MEDICAL, LLC (US) | 2024-04-11 | — | — | US | disclosed |
| EP-4343926-A1 | COOLING STRUCTURE, BATTERY UNIT, AND COOLING STRUCTURE MANUFACTURING METHOD | NIPPON STEEL CORPORATION (JP) | 2024-03-27 | — | — | EP | disclosed |
| WO-2024055011-A1 | MATERIAL COMPOSITIONS AND METHODS OF USE IMPROVING RNA STABILITY | TEAM MEDICAL, LLC (US) | 2024-03-14 | — | — | WO | disclosed |
| CN-117651766-A | Phytase variants with improved stability and IP4 activity | 生化酶股份有限公司 | 2024-03-05 | — | — | CN | disclosed |
| CN-117642504-A | Phytase variants | 生化酶股份有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-4735902-A | ORGANIC SUBSTRATES SUBJECT TO DEGRADATION BY OXIDATION OR FREE RADICALS | PERSTORP AB (SE) | 1988-04-05 | — | — | US | disclosed |
| US-4734283-A | REMOVAL OF CADMIUM FROM BODY | PERSTORP AB (SE) | 1988-03-29 | — | — | US | disclosed |
| EP-0252227-A2 | Use of inositol triphosphate in the treatment of metal intoxication | PERSTORP AB (SE) | 1988-01-13 | — | — | EP | disclosed |
| US-4718482-A | FINS FOR AUTOMOBILE OR HOME AIR CONDITIONERS; SURFACE TREATED ALUMINUM | MITSUBISHI ALUMINUM KABUSHIKI KAISHA (JP) | 1988-01-12 | — | — | US | disclosed |
| EP-0179441-A2 | A method of making a food composition containing inositoltriphosphate and the composition | Sirén, Matti (CH) | 1986-04-30 | — | — | EP | disclosed |
| EP-0179442-A2 | Stabilized composition containing inositoltriphosphate and method for stabilizing the composition | PERSTORP AB (SE) | 1986-04-30 | — | — | EP | disclosed |
| EP-0179440-A1 | Inositoltriphosphate, a method for preparing same and a composition containing same | PERSTORP AB (SE) | 1986-04-30 | — | — | EP | disclosed |
| EP-0179439-A1 | A pharmaceutical composition and a method for preparing same | Sirén, Matti (CH) | 1986-04-30 | — | — | EP | disclosed |
| US-4265780-A | PHOSPHORIC ACID ESTERS OF MYOINOSITOL | NIPPON PAINT CO., LTD. (JP) | 1981-05-05 | — | — | US | disclosed |
| US-4187127-A | INOSITOL PHOSPHATE, A TITANIUM FLUORIDE | NIHON PARKERIZING CO., LTD. (JP) | 1980-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115595-A1 | MATERIAL COMPOSITIONS AND METHODS OF USE IMPROVING RNA STABILITY | RBM22, HNRNPUL2, HNRNPUL1 | ITPR3 3547/4885ITPR1 3238/4885ITPR2 3622/4885 |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | ITPR3 3393/4885ITPR1 2607/4885ITPR2 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.